Drugs. 1990;40:33-7. doi: 10.2165/00003495-199000401-00008.

Primary prevention of coronary heart disease in the Federal Republic of Germany. Analysis of cost-effectiveness.

Drugs

G Assmann, H Schulte

PMID: 2127007 DOI: 10.2165/00003495-199000401-00008

Abstract

The cost-effectiveness of a primary prevention strategy for coronary heart disease is reviewed in this paper. Five subgroups were identified, depending on the degree of medical intervention required to achieve a target low density lipoprotein (LDL)-cholesterol level of less than 4.15 mmol/L. One group required no intervention and, apart from initial screening costs, no further treatment costs were incurred. The cost-effectiveness of medical intervention in the other groups was calculated by use of mathematical models to predict the incidence of coronary heart disease. According to this analysis, life-years saved per 1000 individuals and cost per life-years saved increased as the intensity of intervention increased. In individuals in whom a reduction in total cholesterol was required, life expectancy did not improve substantially, but the onset of coronary heart disease was deferred until an older age. Cholesterol-lowering interventions are unlikely to result in important savings to the health care system, as the benefit of treatment is rather reflected in terms of reduced mortality and improved quality of life. Total costs (in Deutschmarks [DM]) per life-year saved in this analysis were DM30,000-40,000 in men and DM86,000-110,000 in women.

Similar articles

References

1. Eur Heart J. 1988 May;9(5):571-600 - PubMed
2. JAMA. 1986 Nov 28;256(20):2835-8 - PubMed
3. Eur Heart J. 1987 Jan;8(1):77-88 - PubMed
4. Lancet. 1981 Dec 12;2(8259):1303-10 - PubMed

MeSH terms

• Coronary Disease / economics
• Coronary Disease / prevention & control
• Cost-Benefit Analysis
• Germany, West
• Humans

Publication Types

• Journal Article
• Review

LinkOut - more resources

• Full Text Sources
  • Springer
  • Ovid Technologies, Inc.
• Medical
  • Genetic Alliance